Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
9MW2821 is China's first, global second Nectin-4 targeted ADC being investiated for triple negative breast cancer. It is also being studied in more than 10 different solid tumors.
Lead Product(s): 9MW2821
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2024
Details:
9MW2821 is a site-specific conjugated novel Nectin-4-targeting ADC, which is being evaluated for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Lead Product(s): 9MW2821
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2024
Details:
Maiweijian (denosumab) is a fully human recombinant anti-RANKL monoclonal antibody, which is approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: Maiweijian
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
9MW2821 is a site-specific conjugated novel Nectin-4-targeting ADC, which is being evaluated for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Lead Product(s): 9MW2821
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
MW032 (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia. It is a RANK ligand inhibitor, which is being evaluated for treament of bone metastases from solid tumors.
Lead Product(s): Denosumab
Therapeutic Area: Oncology Product Name: MW032
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
7MW3711 is a novel antibody-drug conjugate targeting B7-H3, which is a member of the B7 ligand family and is overexpressed in most cancer type. It is being evaluated for the treatment of advanced malignant solid tumor.
Lead Product(s): 7MW3711
Therapeutic Area: Oncology Product Name: 7MW3711
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
9MW3011 is an anti-TMPRSS6 antibody which can upregulate the level of hepcidin expressed by hepatocytes through specific binding. It is being evaluated for the treatment of β-thalassemia and polycythemia vera.
Lead Product(s): 9MW3011
Therapeutic Area: Genetic Disease Product Name: DISC-3405
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Disc medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
8MW0511 is a G-CSF inhibitor, protein drug candidate, which is currently being evaluated for the treatment of adult patients with non-myeloid malignant neoplasms manifested by febrile neutropenia.
Lead Product(s): 8MW0511
Therapeutic Area: Hematology Product Name: 8MW0511
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
9MW2821 is China's first, global second Nectin-4 targeted ADC approved for pivotal clinical study. The multiple ongoing clinical studies include more than 10 different solid tumors, evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity.
Lead Product(s): 9MW2821,Toripalimab
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
9MW2821 is China's first, global second Nectin-4 targeted ADC, which is investigated in combination with PD-1 inhibitor for the treatment of locally advanced or metastatic urothelial carcinoma.
Lead Product(s): 9MW2821,Undisclosed
Therapeutic Area: Oncology Product Name: 9MW2821
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023